129 related articles for article (PubMed ID: 11420460)
1. In situ adenocarcinoma of the bladder.
Chan TY; Epstein JI
Am J Surg Pathol; 2001 Jul; 25(7):892-9. PubMed ID: 11420460
[TBL] [Abstract][Full Text] [Related]
2. Villous adenoma of the urinary tract: a lesion frequently associated with malignancy.
Seibel JL; Prasad S; Weiss RE; Bancila E; Epstein JI
Hum Pathol; 2002 Feb; 33(2):236-41. PubMed ID: 11957151
[TBL] [Abstract][Full Text] [Related]
3. Urothelial Carcinoma In Situ of the Bladder With Glandular Differentiation: Report of 92 Cases.
Yang Z; Epstein JI
Am J Surg Pathol; 2018 Jul; 42(7):971-976. PubMed ID: 29683821
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive urothelial carcinoma of the bladder with glandular differentiation: report of 24 cases.
Miller JS; Epstein JI
Am J Surg Pathol; 2009 Aug; 33(8):1241-8. PubMed ID: 19440144
[TBL] [Abstract][Full Text] [Related]
5. Urothelial carcinoma with villoglandular differentiation: a study of 14 cases.
Lim M; Adsay NV; Grignon D; Osunkoya AO
Mod Pathol; 2009 Oct; 22(10):1280-6. PubMed ID: 19593329
[TBL] [Abstract][Full Text] [Related]
6. [Clinical study of carcinoma in situ of the urinary bladder].
Harada Y; Seguchi T; Nonomura N; Kojima Y; Miki T; Okuyama A
Nihon Hinyokika Gakkai Zasshi; 1998 Aug; 89(8):693-7. PubMed ID: 9780653
[TBL] [Abstract][Full Text] [Related]
7. [Urethral recurrence of invasive carcinoma following BCG treatment for bladder Ca in situ].
Ruoppolo M; Gozo M; Milesi R; Spina R; Fragapane G
Urologia; 2010; 77 Suppl 17():72-7. PubMed ID: 21308679
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases.
Guo CC; Fine SW; Epstein JI
Am J Surg Pathol; 2006 Jul; 30(7):883-91. PubMed ID: 16819332
[TBL] [Abstract][Full Text] [Related]
9. The case for conservative management in the treatment of patients with non-muscle-invasive micropapillary bladder carcinoma without carcinoma in situ.
Gaya JM; Palou J; Algaba F; Arce J; Rodríguez-Faba O; Villavicencio H
Can J Urol; 2010 Oct; 17(5):5370-6. PubMed ID: 20974029
[TBL] [Abstract][Full Text] [Related]
10. Urachal carcinomas of the nonglandular type: salient features and considerations in pathologic diagnosis.
Paner GP; Barkan GA; Mehta V; Sirintrapun SJ; Tsuzuki T; Sebo TJ; Jimenez RE
Am J Surg Pathol; 2012 Mar; 36(3):432-42. PubMed ID: 22301493
[TBL] [Abstract][Full Text] [Related]
11. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
12. Clear cell carcinoma of the urinary bladder: a report and comparison of four tumors of mullerian origin and nine of probable urothelial origin with discussion of histogenesis and diagnostic problems.
Oliva E; Amin MB; Jimenez R; Young RH
Am J Surg Pathol; 2002 Feb; 26(2):190-7. PubMed ID: 11812940
[TBL] [Abstract][Full Text] [Related]
13. Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guérin for carcinoma in situ of the bladder.
Merz VW; Marth D; Kraft R; Ackermann DK; Zingg EJ; Studer UE
Br J Urol; 1995 Feb; 75(2):180-4. PubMed ID: 7850322
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy.
Ajili F; Kourda N; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Feb; 37(1):56-61. PubMed ID: 23383616
[TBL] [Abstract][Full Text] [Related]
15. Bladder sparing approach for initial T1G3 bladder cancer: Do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients.
Denzinger S; Otto W; Fritsche HM; Roessler W; Wieland WF; Hartmann A; Burger M
Int J Urol; 2007 Nov; 14(11):995-9; discussion 999. PubMed ID: 17956523
[TBL] [Abstract][Full Text] [Related]
16. Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma.
Amin MB; Ro JY; el-Sharkawy T; Lee KM; Troncoso P; Silva EG; Ordóñez NG; Ayala AG
Am J Surg Pathol; 1994 Dec; 18(12):1224-32. PubMed ID: 7977945
[TBL] [Abstract][Full Text] [Related]
17. Long-term risk of progression of carcinoma in situ of the bladder and impact of bacille Calmette-Guérin immunotherapy on the outcome.
Zieger K; Jensen KM
Scand J Urol Nephrol; 2011 Dec; 45(6):411-8. PubMed ID: 21793636
[TBL] [Abstract][Full Text] [Related]
18. Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup.
Herr HW; Wartinger DD; Fair WR; Oettgen HF
J Urol; 1992 Apr; 147(4):1020-3. PubMed ID: 1552578
[TBL] [Abstract][Full Text] [Related]
19. Flat urothelial carcinoma in situ of the bladder with glandular differentiation.
Lopez-Beltran A; Jimenez RE; Montironi R; Patriarca C; Blanca A; Menendez CL; Algaba F; Cheng L
Hum Pathol; 2011 Nov; 42(11):1653-9. PubMed ID: 21531007
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-year experience.
Pansadoro V; Emiliozzi P; de Paula F; Scarpone P; Pansadoro A; Sternberg CN
Urology; 2002 Feb; 59(2):227-31. PubMed ID: 11834391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
